ArticleNature microbiology2018
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Open access · greenAbstract read
In one paragraph
Article in Nature microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 87 citations in OpenAlex.
- Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses.Nature communications · 2026Article
- Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus.Viruses · 2026Review
- Mapping the global evidence base of bundibugyo ebolavirus disease: a systematic scoping review of research gaps and preparedness priorities.BMC infectious diseases · 2026Article
- Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification.Nature communications · 2025Article
- Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification.bioRxiv : the preprint server for biology · 2025Article
- Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses.Nature communications · 2025Article
- Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus.Npj viruses · 2025Article
- Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GPNature communications · 2025Article
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement systemCommunications biology · 2024Article
- Developments in Negative-Strand RNA Virus Reverse Genetics.Microorganisms · 2024Review
- Article
- Design of universal Ebola virus vaccine candidates via immunofocusing.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membrane.Research square · 2023Article
- A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses.The Journal of infectious diseases · 2023Article
- Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin.Cell reports · 2023Article
- Design of universal Ebola virus vaccine candidatesbioRxiv : the preprint server for biology · 2023Article
- Viral Membrane Fusion: A Dance Between Proteins and Lipids.Annual review of virology · 2023Review
- A high-throughput single-particle imaging platform for antibody characterization and a novel competition assay for therapeutic antibodies.Scientific reports · 2023Article
- Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin.Pharmacology & therapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 6 institutions in 1 country.
Andrew I FlyakDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA.
Natalia KuzminaDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Charles D MurinDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Christopher BryanIntegral Molecular, Inc., Philadelphia, PA, USA.
Edgar DavidsonIntegral Molecular, Inc., Philadelphia, PA, USA.
Pavlo GilchukVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Christopher P GulkaDepartment of Chemistry, Vanderbilt University Medical Center, Nashville, TN, USA.
Philipp A IlinykhDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Xiaoli ShenDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Kai HuangDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Palaniappan RamanathanDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Hannah TurnerDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Marnie L FuscoDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.
Rebecca LampleyVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Nurgun KoseVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Hannah KingVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Gopal SapparapuVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Benjamin J DoranzIntegral Molecular, Inc., Philadelphia, PA, USA.
Thomas G KsiazekDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
David W WrightDepartment of Chemistry, Vanderbilt University Medical Center, Nashville, TN, USA.
Erica Ollmann SaphireDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA. alexander.bukreyev@utmb.edu.ORCID http://orcid.org/0000-0002-0342-4824
James E CroweDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN, USA. james.crowe@vanderbilt.edu.ORCID http://orcid.org/0000-0002-0049-1079
Galveston College · USVanderbilt University Medical Center · USScripps Research Institute · USIntegral Molecular (United States) · USCalifornia Institute of Technology · USVanderbilt University · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MMechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6MSupplemental Research Project (SRP)U19AI109711 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2014 to 2018
$26.6MEBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSISR01AI067927 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2006 to 2013
$3.6MNCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NCRR NIH HHS UL1 RR024975NIAID NIH HHS HHSN272201400058CNIAID NIH HHS R01 AI067927NIAID NIH HHS U19 AI109711NIAID NIH HHS U19 AI109762
Abstract
Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies have been developed in the past to treat EBOV infection, including the antibody cocktail ZMapp, which has been shown to be effective in nonhuman primate models of infection
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralBinding SitesChlorocebus aethiopsCross ReactionsEbolavirusEpitopesFerretsGuinea PigsHemorrhagic Fever, EbolaHumansMembrane GlycoproteinsMiceModels, MolecularProtein BindingAntibodies, NeutralizingAntibodies, ViralEpitopesMembrane GlycoproteinsViral Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.